The SEC’s Big RIA Reclassification: A Small Change With Major M&A Ripples

Business merger collaboration illustration

The Securities and Exchange Commission has proposed a major redefining of what counts as a “small entity” in the world of registered investment advisers (RIAs) — and the change is so dramatic that it would instantly reclassify about 96% of all RIAs as small instead of large.

This is far more than a paperwork adjustment — it’s a shift with potential ripple effects across mergers, acquisitions, compliance operations, and even the momentum of breakaway advisers exploring independence.

Originally reported by PLANADVISER. Explore the full article here: SEC RIA ‘Small Entity’ Redefinition Could Affect M&A

A Massive Jump in the Definition of “Small”

Currently, an RIA is considered a small entity only if it manages less than $25 million in assets. Under the new SEC proposal, “small” would skyrocket to include firms with under $1 billion AUM.

“It’s an absurd jump … a 40-times leap,” says Peter Campagna of Wise Rhino Group. “But I think it’s more about relieving administrative burden. You shouldn’t have the same scrutiny as BlackRock if you’re managing under $1 billion.”

The intention is to reduce regulatory strain on most RIAs — but that relief could still trigger new complications during merger transitions or compliance restructuring.

Why M&A Integration Could Get Tricky

Kim Kovalski of MarshBerry notes that although compliance relief is welcome, the shift introduces integration challenges when formerly “small” firms merge upward. These may include:

  • Upgrading firmwide policies
  • Reworking reporting practices
  • Rebuilding compliance staffing
  • Implementing phased integration plans

These aren’t deal breakers — but they’re hurdles that growing RIAs must prepare for strategically.

M&A Isn’t Slowing Down Anytime Soon

Despite potential complications, the RIA acquisition market remains strong. Last year alone hit record-breaking activity, with buyers still eager and valuations holding steady.

Some firm owners may even feel less urgency to sell if their classification shifts to “small,” reducing compliance pressure.

A Potential Surge in Breakaway Advisers

Campagna also predicts a possible spike in breakaway advisers — professionals leaving large wirehouses to launch independent wealth firms.

“There were advisers who weren’t doing it that would do it now,” Campagna says. “That’s a whole lot of talented people.”

Why Professionals Everywhere Should Pay Attention

Regulatory shifts like this highlight a universal truth across all licensed fields — whether in finance, real estate, insurance, or healthcare — the compliance landscape can evolve fast.

Staying educated, licensed, and current is essential. For professionals seeking new opportunities, expanding certifications, or pivoting industries, Cameron Academy remains a trusted, nationwide resource with programs spanning all 50 states.

In a world where regulation shapes opportunity, the professionals who stay informed — and stay licensed — are the ones who rise to the top.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

The Remote Work Revolution: Redefining Real Estate

Imagine a morning where the commute is just a few steps from your bedroom to your home office. This is the reality for many in today's post-pandemic world, where remote work has become a staple of the modern workforce.

By |December 2, 2024|Categories: Article, Real Estate, Remote Work|Tags: , |0 Comments

CRISPR: The Future of Gene Editing and Its Clinical Implications

CRISPR technology has become the frontrunner in genome editing, surpassing earlier methods like zinc finger nucleases and transcription activator-like effector nucleases. The recent FDA approval of the CRISPR-Cas9 drug, exa-cel, marks a significant milestone particularly for treating sickle cell disease and transfusion-dependent beta thalassemia.

By |December 1, 2024|Categories: Article, Biotechnology, Medicine|Tags: , |0 Comments

AI Revolution in Oncology: Transformative Potential or Overhyped?

In recent years, artificial intelligence has emerged as a revolutionary tool in the field of oncology. AI's integration into healthcare transcends buzzwords, transforming cancer diagnosis, treatment personalization, and drug discovery.

AI in Radiology: A Double-Edged Sword

The rapid advancements in artificial intelligence (AI) are transforming the landscape of radiology, promising to enhance diagnostic accuracy and support personalized medicine. However, as this technology becomes more integral to medical imaging, it brings with it a host of ethical and societal considerations that cannot be ignored.

Humanity at the Crossroads: Ethical Implications of AI in Medicine

AI's promise in healthcare is undeniable, with its ability to uncover hidden disease patterns and predict illnesses. However, the reliance on historical data can exacerbate existing biases, particularly affecting marginalized communities such as the LGBTQIA+ and certain ethnic and racial groups.

The Future of Telemedicine: Challenges and Opportunities Beyond the Pandemic

Telemedicine stands out as a transformative force, offering a lifeline to patients and providers alike. As we move beyond the pandemic, the challenge is to integrate this technology without escalating costs or overshadowing the indispensable role of in-person consultations.

By |November 30, 2024|Categories: Article, Healthcare, Technology|Tags: , |0 Comments